PE20211599A1 - Administracion prolongada de lasmiditan por la noche para la prevencion de la migrana - Google Patents
Administracion prolongada de lasmiditan por la noche para la prevencion de la migranaInfo
- Publication number
- PE20211599A1 PE20211599A1 PE2021000286A PE2021000286A PE20211599A1 PE 20211599 A1 PE20211599 A1 PE 20211599A1 PE 2021000286 A PE2021000286 A PE 2021000286A PE 2021000286 A PE2021000286 A PE 2021000286A PE 20211599 A1 PE20211599 A1 PE 20211599A1
- Authority
- PE
- Peru
- Prior art keywords
- prevention
- night
- migrana
- meditan
- prolonged administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
Abstract
La presente invencion se refiere al uso prolongado de lasmiditan por la noche para la prevencion de la migrana, particularmente la migrana resistente al tratamiento que se define en el presente documento como migrana refractaria a dos o mas esquemas de prevencion o tratamiento previos de monoterapia y/o terapia doble.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862726585P | 2018-09-04 | 2018-09-04 | |
| PCT/US2019/049340 WO2020051137A1 (en) | 2018-09-04 | 2019-09-03 | Chronic nightly dosing of lasmiditan for migraine prevention |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211599A1 true PE20211599A1 (es) | 2021-08-18 |
Family
ID=68051892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000286A PE20211599A1 (es) | 2018-09-04 | 2019-09-03 | Administracion prolongada de lasmiditan por la noche para la prevencion de la migrana |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US12138254B2 (es) |
| EP (2) | EP3846810B1 (es) |
| JP (2) | JP7321256B2 (es) |
| KR (1) | KR102649644B1 (es) |
| CN (1) | CN112638383A (es) |
| AU (3) | AU2019336667B2 (es) |
| BR (1) | BR112021002945A2 (es) |
| CA (1) | CA3111205A1 (es) |
| CL (1) | CL2021000529A1 (es) |
| CO (1) | CO2021002766A2 (es) |
| CR (1) | CR20210126A (es) |
| DK (1) | DK3846810T3 (es) |
| DO (1) | DOP2021000039A (es) |
| EA (1) | EA202190440A1 (es) |
| EC (1) | ECSP21015491A (es) |
| ES (1) | ES2967665T3 (es) |
| FI (1) | FI3846810T3 (es) |
| HR (1) | HRP20231587T1 (es) |
| HU (1) | HUE064519T2 (es) |
| IL (1) | IL281208B2 (es) |
| JO (1) | JOP20210033A1 (es) |
| LT (1) | LT3846810T (es) |
| MA (1) | MA53551B1 (es) |
| MD (1) | MD3846810T2 (es) |
| MX (1) | MX2021002474A (es) |
| MY (1) | MY199662A (es) |
| PE (1) | PE20211599A1 (es) |
| PH (1) | PH12021550448A1 (es) |
| PL (1) | PL3846810T3 (es) |
| PT (1) | PT3846810T (es) |
| RS (1) | RS64857B1 (es) |
| SG (1) | SG11202101530PA (es) |
| SI (1) | SI3846810T1 (es) |
| TW (1) | TWI826514B (es) |
| UA (1) | UA129587C2 (es) |
| WO (1) | WO2020051137A1 (es) |
| ZA (1) | ZA202100666B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102753171A (zh) | 2009-04-02 | 2012-10-24 | 科鲁西德制药公司 | 2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲酰胺的组合物 |
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| HK1232218A1 (zh) | 2014-02-05 | 2018-01-05 | Merck Sharp & Dohme Llc | Cgrp-活性化合物的片剂制剂 |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| CA3190176A1 (en) * | 2020-07-29 | 2022-02-03 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| AU2021409718A1 (en) | 2020-12-22 | 2023-07-13 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| MX2024003952A (es) | 2021-09-27 | 2024-05-27 | Allergan Pharmaceuticals Int Ltd | Combinación que comprende atogepant para tratar la migraña. |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US5385912A (en) | 1991-03-08 | 1995-01-31 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Multicyclic tertiary amine polyaromatic squalene synthase inhibitors |
| US5360735A (en) | 1992-01-08 | 1994-11-01 | Synaptic Pharmaceutical Corporation | DNA encoding a human 5-HT1F receptor, vectors, and host cells |
| US5521196A (en) | 1994-10-05 | 1996-05-28 | Eli Lilly And Company | 5-HT1F agonists for the treatment of migraine |
| US5698571A (en) * | 1994-10-05 | 1997-12-16 | Eli Lilly And Company | 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine |
| US5521197A (en) | 1994-12-01 | 1996-05-28 | Eli Lilly And Company | 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists |
| PL322843A1 (en) | 1995-03-20 | 1998-02-16 | Lilly Co Eli | 5-substituted 3-91,2,3,6-tetrahydropyridin-4-yl)- and 3-9piperydin-4-4-yl0-1h-indoles nevel 5-htif natagonists |
| WO1997013512A1 (en) | 1995-10-10 | 1997-04-17 | Eli Lilly And Company | N-[2-substituted-3-(2-aminoethyl)-1h-indol-5-yl]-amides: new 5-ht1f agonists |
| US5708187A (en) | 1996-06-27 | 1998-01-13 | Eli Lilly And Company | 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists |
| PL331882A1 (en) | 1996-08-28 | 1999-08-16 | Lilly Co Eli | Substituted 1,2,3,4-tetrahydro-2-dibenzofurane amines and 2-amino cyclohepta[b]benzofuranes |
| US5792763A (en) | 1996-10-08 | 1998-08-11 | Eli Lilly And Company | Serotonin 5-HT1F agonists |
| ZA979961B (en) | 1996-11-15 | 1999-05-05 | Lilly Co Eli | 5-HT1F agonists |
| EP0875513A1 (en) | 1997-04-14 | 1998-11-04 | Eli Lilly And Company | Substituted heteroaromatic 5-HT 1F agonists |
| ID23053A (id) | 1997-06-04 | 2000-01-20 | Lilly Co Eli | Karboksamida yang digunakan sebagai agonis 5-ht <if> |
| US5905084A (en) | 1997-11-14 | 1999-05-18 | Eli Lilly And Company | 5-HTIF -agonists effective in treating migraine |
| US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
| WO2000000490A2 (en) | 1998-06-26 | 2000-01-06 | Eli Lilly And Company | 5-ht1f agonists |
| ATE252572T1 (de) | 1998-06-30 | 2003-11-15 | Lilly Co Eli | 5-ht1f agonisten |
| AU1937300A (en) | 1998-12-11 | 2000-06-26 | Eli Lilly And Company | Indole derivatives and their use as 5-HT1F agonists |
| CN1149195C (zh) | 1999-02-10 | 2004-05-12 | 伊莱利利公司 | 5－ht1f激动剂 |
| US6777428B1 (en) | 1999-02-10 | 2004-08-17 | Eli Lilly And Company | 5-HT1f agonist |
| WO2000050426A2 (en) | 1999-02-26 | 2000-08-31 | Eli Lilly And Company | Furo[3, 2-b]pyridines as 5-ht1f agonists |
| ATE384036T1 (de) | 2000-07-13 | 2008-02-15 | Merck Patent Gmbh | Chirale verbindungen i |
| US6650463B2 (en) | 2001-03-13 | 2003-11-18 | Seiko Epson Corporation | Electrophoretic display device |
| WO2003000245A1 (en) | 2001-06-22 | 2003-01-03 | Poseidon Pharmaceuticals A/S | Compounds for use in disorders associated with mast cell or basophil activity |
| TWI263497B (en) | 2002-03-29 | 2006-10-11 | Lilly Co Eli | Pyridinoylpiperidines as 5-HT1F agonists |
| AU2003295782A1 (en) | 2002-11-22 | 2004-06-18 | Bristol-Myers Squibb Company | Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers |
| GB0308186D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| CA2518839A1 (en) | 2003-04-18 | 2004-11-04 | Eli Lilly And Company | (piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht1f agonists |
| WO2004099127A1 (en) | 2003-05-07 | 2004-11-18 | Novo Nordisk A/S | Novel compounds as kinase inhibitors |
| WO2005007621A2 (en) | 2003-05-30 | 2005-01-27 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| UA82711C2 (en) | 2003-09-12 | 2008-05-12 | Эли Лилли Энд Компани | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| GB0510143D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| WO2006048771A1 (en) | 2004-11-04 | 2006-05-11 | Addex Pharmaceuticals Sa | Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| MX2007006109A (es) | 2004-12-01 | 2007-10-04 | Devgen Nv | Derivados de tiazol sustituidos en 5-carboxamido que interactuan con canales de iones, en particular con canales ionicos de la familia de kv. |
| KR20060067738A (ko) | 2004-12-15 | 2006-06-20 | 주식회사 대웅제약 | 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 신규한 ｎ-아릴아마이드 유도체 및 이를함유하는 약제학적 조성물 |
| US20060178349A1 (en) | 2005-01-24 | 2006-08-10 | Pozen Inc. | Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID |
| DE102005016634A1 (de) | 2005-04-12 | 2006-10-19 | Merck Patent Gmbh | Neuartige Aza-Hetercyclen als Kinase-Inhibitoren |
| KR100976063B1 (ko) | 2007-03-16 | 2010-08-17 | 동아제약주식회사 | 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법 |
| CN102753171A (zh) | 2009-04-02 | 2012-10-24 | 科鲁西德制药公司 | 2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲酰胺的组合物 |
| CA2795062A1 (en) * | 2010-04-02 | 2011-10-06 | Colucid Pharmaceuticals, Inc. | Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists |
| PL3551617T3 (pl) | 2016-12-06 | 2021-12-20 | Colucid Pharmaceuticals, Inc. | Kompozycje i sposoby związane z pirydynoilopiperydynowymi agonistami 5-HT<sub>1F</sub> |
| TWI754772B (zh) | 2017-09-06 | 2022-02-11 | 美商美國禮來大藥廠 | 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法 |
-
2019
- 2019-09-02 TW TW108131567A patent/TWI826514B/zh active
- 2019-09-03 EA EA202190440A patent/EA202190440A1/ru unknown
- 2019-09-03 PL PL19773583.0T patent/PL3846810T3/pl unknown
- 2019-09-03 IL IL281208A patent/IL281208B2/en unknown
- 2019-09-03 UA UAA202100630A patent/UA129587C2/uk unknown
- 2019-09-03 MY MYPI2021001043A patent/MY199662A/en unknown
- 2019-09-03 PT PT197735830T patent/PT3846810T/pt unknown
- 2019-09-03 CN CN201980055464.3A patent/CN112638383A/zh active Pending
- 2019-09-03 JO JOP/2021/0033A patent/JOP20210033A1/ar unknown
- 2019-09-03 PE PE2021000286A patent/PE20211599A1/es unknown
- 2019-09-03 SG SG11202101530PA patent/SG11202101530PA/en unknown
- 2019-09-03 WO PCT/US2019/049340 patent/WO2020051137A1/en not_active Ceased
- 2019-09-03 MD MDE20210640T patent/MD3846810T2/ro unknown
- 2019-09-03 ES ES19773583T patent/ES2967665T3/es active Active
- 2019-09-03 BR BR112021002945-1A patent/BR112021002945A2/pt unknown
- 2019-09-03 EP EP19773583.0A patent/EP3846810B1/en active Active
- 2019-09-03 HR HRP20231587TT patent/HRP20231587T1/hr unknown
- 2019-09-03 KR KR1020217005977A patent/KR102649644B1/ko active Active
- 2019-09-03 MA MA53551A patent/MA53551B1/fr unknown
- 2019-09-03 SI SI201930647T patent/SI3846810T1/sl unknown
- 2019-09-03 JP JP2021512380A patent/JP7321256B2/ja active Active
- 2019-09-03 FI FIEP19773583.0T patent/FI3846810T3/fi active
- 2019-09-03 MX MX2021002474A patent/MX2021002474A/es unknown
- 2019-09-03 RS RS20231107A patent/RS64857B1/sr unknown
- 2019-09-03 HU HUE19773583A patent/HUE064519T2/hu unknown
- 2019-09-03 AU AU2019336667A patent/AU2019336667B2/en active Active
- 2019-09-03 US US17/271,950 patent/US12138254B2/en active Active
- 2019-09-03 CA CA3111205A patent/CA3111205A1/en active Pending
- 2019-09-03 LT LTEPPCT/US2019/049340T patent/LT3846810T/lt unknown
- 2019-09-03 DK DK19773583.0T patent/DK3846810T3/da active
- 2019-09-03 EP EP23195738.2A patent/EP4279132A3/en active Pending
- 2019-09-03 CR CR20210126A patent/CR20210126A/es unknown
-
2021
- 2021-01-29 ZA ZA2021/00666A patent/ZA202100666B/en unknown
- 2021-03-01 CO CONC2021/0002766A patent/CO2021002766A2/es unknown
- 2021-03-02 PH PH12021550448A patent/PH12021550448A1/en unknown
- 2021-03-02 DO DO2021000039A patent/DOP2021000039A/es unknown
- 2021-03-03 CL CL2021000529A patent/CL2021000529A1/es unknown
- 2021-03-04 EC ECSENADI202115491A patent/ECSP21015491A/es unknown
-
2022
- 2022-12-22 AU AU2022291568A patent/AU2022291568A1/en not_active Abandoned
-
2023
- 2023-07-25 JP JP2023120471A patent/JP7543497B2/ja active Active
-
2025
- 2025-02-28 AU AU2025201479A patent/AU2025201479A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211599A1 (es) | Administracion prolongada de lasmiditan por la noche para la prevencion de la migrana | |
| CO2018012894A2 (es) | Derivados de pirazol como inhibidores de calicreína plasmática | |
| MX378969B (es) | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres. | |
| CL2017000080A1 (es) | Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer | |
| CL2019003078A1 (es) | Nuevos derivados de pirazol bicíclicos. | |
| NI201400104A (es) | Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento | |
| MX2018011785A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue. | |
| MX2019013878A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue. | |
| CL2019001996A1 (es) | Usos terapéuticos de un polvo de insectos. | |
| CO2018008421A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CR20190447A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue | |
| MX386782B (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
| MX2019013893A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue. | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| CR20180495A (es) | Deribados de indol sustituidos como inhibidores de replicación viral del dengue | |
| MX374749B (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer. | |
| CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
| CL2019002480A1 (es) | Derivados de pirazol como inhibidores de bromodominio. | |
| CL2021000129A1 (es) | Apirasas solubilizadas, métodos y usos | |
| MX2019009909A (es) | Composiciones farmaceuticas para terapia de combinacion. | |
| MX384394B (es) | Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas. | |
| EP3843715C0 (en) | THERAPY OF HIGH-RISK HUMAN PAPILLOMAVIRUS INFECTIONS | |
| BR112016016674A2 (pt) | Agente terapêutico ou profilático para uso no tratamento de esclerose múltipla | |
| EA201991866A1 (ru) | Комбинированная терапия | |
| UY33788A (es) | Derivados de arilsulfonamida para la prevención o el tratamiento de trastornos oftalmológicos específicos |